Insulet Corporation (PODD) Given Consensus Rating of “Buy” by Brokerages

Insulet Corporation (NASDAQ:PODD) has received an average rating of “Buy” from the eighteen research firms that are covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $50.20.

PODD has been the topic of a number of recent research reports. Jefferies Group LLC restated a “buy” rating and set a $58.00 price objective (up previously from $48.00) on shares of Insulet Corporation in a research note on Wednesday, August 9th. BidaskClub upgraded Insulet Corporation from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 27th. Canaccord Genuity restated a “hold” rating and set a $42.00 price objective on shares of Insulet Corporation in a research note on Friday, May 26th. Cowen and Company restated a “buy” rating and set a $52.00 price objective on shares of Insulet Corporation in a research note on Friday, July 14th. Finally, ValuEngine upgraded Insulet Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd.

Large investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in Insulet Corporation by 0.5% in the second quarter. FMR LLC now owns 8,687,487 shares of the medical instruments supplier’s stock valued at $445,755,000 after buying an additional 39,836 shares during the period. Capital Research Global Investors increased its stake in Insulet Corporation by 2.5% in the second quarter. Capital Research Global Investors now owns 5,883,633 shares of the medical instruments supplier’s stock valued at $301,889,000 after buying an additional 145,724 shares during the period. Vanguard Group Inc. increased its stake in Insulet Corporation by 2.2% in the second quarter. Vanguard Group Inc. now owns 4,655,119 shares of the medical instruments supplier’s stock valued at $238,854,000 after buying an additional 98,272 shares during the period. BlackRock Inc. increased its stake in Insulet Corporation by 7,285.2% in the first quarter. BlackRock Inc. now owns 4,194,117 shares of the medical instruments supplier’s stock valued at $180,724,000 after buying an additional 4,137,326 shares during the period. Finally, Clearbridge Investments LLC increased its stake in Insulet Corporation by 64.2% in the first quarter. Clearbridge Investments LLC now owns 2,379,224 shares of the medical instruments supplier’s stock valued at $102,521,000 after buying an additional 930,062 shares during the period.

Insulet Corporation (NASDAQ:PODD) traded down 1.18% during trading on Tuesday, hitting $57.18. The stock had a trading volume of 200,281 shares. The company’s 50-day moving average is $52.72 and its 200 day moving average is $46.15. Insulet Corporation has a 52 week low of $30.69 and a 52 week high of $58.48. The firm’s market cap is $3.32 billion.

Insulet Corporation (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The firm had revenue of $110 million for the quarter, compared to analyst estimates of $106.23 million. During the same quarter last year, the company earned ($0.08) EPS. The company’s revenue was up 26.0% on a year-over-year basis. Equities analysts expect that Insulet Corporation will post ($0.50) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Insulet Corporation (PODD) Given Consensus Rating of “Buy” by Brokerages” was first posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://baseballnewssource.com/markets/insulet-corporation-podd-given-consensus-rating-of-buy-by-brokerages/1558333.html.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.